Business
Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial
Regulatory clearance enables start of clinical testing and marks transition to clinical-stage companyOn track for initial clinical data to emerge from mid-2026 Oslo, Norway, 20 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Comp
About this update from Zelluna Asa
[{"type":"image","alt":"Zelluna ASA","displaySize":"","headline":null,"caption":"Zelluna ASA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C3Qdgv86SfCXtr_6x5fSRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69","width":300,"height":106}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Regulatory clearance enables start of clinical testing and marks transition to clinical-stage company","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"On track for initial clinical data to emerge from mid-2026","length":58,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":159,"olType":false},{"type":"text","content":"Oslo, Norway, 20 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Company's Clinical Trial Application (CTA) for ZIMA-101, a first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate.","length":517,"tagName":"p"},{"type":"text","content":"Highlights:","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"MHRA and Ethics approvals enable Zelluna to initiate first-in-human clinical trial in the UK","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"Marks Zelluna's transition from preclinical to clinical-stage development","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"First clinical evaluation of Zelluna's proprietary TCR-NK platform technology","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"Trial to assess safety and preliminary activity in patients with advanced solid cancers","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Initial clinical data expected to emerge from mid-2026","length":54,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":391,"olType":false},{"type":"text","content":"The approvals allow Zelluna to in...